Moderna reports ‘robust’ COVID vaccine response in children aged 6-11

US pharmaceutical giant Moderna reports a “robust neutralizing antibody response” to its COVID-19 vaccine in children aged 6-11, and says that it will submit the trial data to global regulators soon.

“We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints,” chief executive Stephane Bancel says in a statement.

Data from clinical trials with more than 4,700 children in the age range “demonstrate strong immune response… one month after the second dose,” Moderna says in the statement.

The results come after Pfizer said last week that its COVID vaccine is 90% effective in preventing symptomatic disease among children aged 5-11.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed